A recent paper makes a compelling case for a new mechanism by which heterozygous mutations in isocitrate dehydrogenases (IDH1/2) undermine gene regulatory mechanisms: 2-hydroxyglutarate (2HG) produced by mutant IDH alters the binding of the chromosomal organiser protein CTCF, disrupting the spatial and regulatory organisation of the genome. A recent paper [2] adds a new twist to the story by demonstrating that IDH mutations affect the binding of the chromatin organiser protein CTCF, which demarcates domains of genome folding [3] . To illustrate the relationship between 3D chromatin domains and CTCF binding, Figure 1 shows high-resolution Hi-C data ( Figure 1A ) and CTCF ChIPsequencing data ( Figure 1B) for the genomic region home to the known glioma oncogene, PDGFRA. The PDGFRA promoter is adjacent to CTCF sites in reverse orientation (green in Figure 1C 
IDH mutations occur with high frequency in gliomas and other human cancers. Mutant IDH enzymes produce the oncometabolite 2HG, which accumulates to high concentrations. 2HG not only changes the metabolic state of IDH mutant cells, butcrucially -inhibits the activity of enzymes that are critical for chromatin structure and gene regulation. Tet enzymes remove DNA methylation [1] and their inhibition by 2HG increases DNA methylation in IDH mutant cells. 2HG also inhibits the Jumanji family of histone demethylases, increasing histone methylation. These and other effects of 2HG [1] perturb gene expression in IDH mutant cells and contribute to tumor formation [1] .
A recent paper [2] adds a new twist to the story by demonstrating that IDH mutations affect the binding of the chromatin organiser protein CTCF, which demarcates domains of genome folding [3] . To illustrate the relationship between 3D chromatin domains and CTCF binding, Figure 1 shows high-resolution Hi-C data ( Figure 1A ) and CTCF ChIPsequencing data ( Figure 1B) for the genomic region home to the known glioma oncogene, PDGFRA. The PDGFRA promoter is adjacent to CTCF sites in reverse orientation (green in Figure 1C ). Illustrating an emerging principle of genome folding [3] , 2 these reverse sites interact with CTCF motifs in convergent (forward) orientation to form a 'loop domain', visible in Hi-C data as a triangle connecting the CTCF sites ( Figure 1A ).
IDH mutant glioma cells lose ~600 CTCF binding events genome-wide and gain ~300, presumably perturbing 3D genome organisation. Loss of CTCF binding correlates with increased DNA methylation, and preferentially occurs at CTCF binding sites with motifs that contain CG dinucleotides as targets of DNA methylation [2] . DNA methylation may not be the only cause of altered CTCF binding in IDH mutant cells: At some sites at least, the reported increase in DNA methylation is smaller than the observed drop in CTCF binding [2] , and increased DNA methylation does not explain the new CTCF binding In normal cells, genes in the same domain show more similar expression than genes located in separate domains, in part because they share access to gene regulatory elements [7] . In this way, spatial segmentation of the genome facilitates the regulation of gene expression. Does altered CTCF binding perturb the 3D organisation of the genome and deregulate gene expression in IDH mutant cells? In support of this idea, the authors demonstrate that genes located in separate domains show more similar expression in IDH mutant cells than in IDH wild type cells [2] . Until high-resolution Hi-C data for IDH mutant cells become available, the precise relationship between altered CTCF binding, genome folding, and gene regulation in IDH mutant cells remains speculative.
Nevertheless, the available data show that in IDH mutant cells the PDGFRA promoter interacts with an enhancer near the FIPL1L gene, almost a million base pairs away (Figure1), and that PDGFRA expression is upregulated [2] .
The drug 5-azacytidine partially restores CTCF binding and downregulates PDGFRA expression in IDH mutant cells [3] . Mechanistically, 5-azacytidine reduces DNA methylation by inhibiting the methyl transferase DNMT1, but has additional effects on chromatin and gene regulation [8] . To further test the hypothesis that increased Clinically, high levels of 2HG may sensitise IDH-mutant tumour cells to other therapeutic approaches [1] . Alternatively, pharmacological inhibition of IDH, or selective inhibition of the abnormal enzymatic activity could be used to specifically target tumour cells [1] . IDH inhibitors can revert the impact of IDH mutations on chromatin state [6] . Whether this includes correction of CTCF binding, genome folding and gene expression is an interesting question that remains to be explored. 
